Nantahala Capital Management LLC Invests $1.39 Million in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Nantahala Capital Management LLC bought a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the company's stock, valued at approximately $1,390,000. Nantahala Capital Management LLC owned 0.20% of Tyra Biosciences at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at $31,000. US Bancorp DE acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $50,000. Aquatic Capital Management LLC bought a new stake in Tyra Biosciences in the fourth quarter valued at approximately $64,000. Wells Fargo & Company MN boosted its holdings in Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock valued at $132,000 after acquiring an additional 3,236 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Tyra Biosciences by 130,587.5% in the 4th quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company's stock valued at $145,000 after acquiring an additional 10,447 shares in the last quarter. Institutional investors own 84.14% of the company's stock.

Insider Buying and Selling

In other Tyra Biosciences news, Director Nina S. Kjellson sold 5,401 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the sale, the director now owns 443,885 shares in the company, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TYRA. UBS Group initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price target for the company. Wedbush restated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $30.83.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA traded up $0.18 during midday trading on Thursday, hitting $10.48. 316,999 shares of the stock traded hands, compared to its average volume of 252,660. The firm has a 50-day moving average of $9.82 and a two-hundred day moving average of $14.00. The firm has a market capitalization of $556.38 million, a P/E ratio of -6.51 and a beta of 1.19. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.05. Equities analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.